Vitamin D receptor protein expression in tumor tissue and prostate cancer progression

Journal of Clinical Oncology

Volumn 29, Issue 17, 2011, Pages 2378-2385

  Hendrickson, Whitney K ^a,b   Flavin, Richard ^c,d   Kasperzyk, Julie L ^a,b   Fiorentino, Michelangelo ^c   Fang, Fang ^a,e   Lis, Rosina ^c   Fiore, Christopher ^c   Penney, Kathryn L ^a,b   Ma, Jing ^b   Kantoff, Philip W ^c   Stampfer, Meir J ^a,b   Loda, Massimo ^a,b   Mucci, Lorelei A ^a,b   Giovannucci, Edward ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; PROSTATE SPECIFIC ANTIGEN; VITAMIN D RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER TISSUE; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PSAMMOMA BODY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; DISEASE PROGRESSION; HUMANS; INCIDENCE; MALE; ONCOGENE PROTEINS, FUSION; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 79959284876     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.9880     Document Type: Article

References (52)

1. Reference deleted
2. Reference deleted
3. Reference deleted
4. Reference deleted
5. Reference deleted
6. Holt SK, Kwon EM, Peters U, et al: Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 18:1929-1933, 2009
7. Luong KV, Nguyen LT: The beneficial role of vitamin D and its analogs in cancer treatment and prevention. Crit Rev Oncol Hematol 73:192-201, 2010
8. Holick MF: Vitamin D: Its role in cancer prevention and treatment. Prog Biophys Mol Biol 92:49-59, 2006
9. Reference deleted
10. Mikhak B, Hunter DJ, Spiegelman D, et al: Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate 67:911-923, 2007 (Pubitemid 46828925)
11. Jacobs ET, Giuliano AR, Martinez ME, et al: Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 89-90:533-537, 2004
12. Platz EA, Leitzmann MF, Hollis BW, et al: Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15:255-265, 2004 (Pubitemid 38988034)
13. Gann PH, Ma J, Hennekens CH, et al: Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5:121-126, 1996
14. Nomura AM, Stemmermann GN, Lee J, et al: Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9:425-432, 1998 (Pubitemid 28466695)
15. Gupta D, Lammersfeld CA, Trukova K, et al: Vitamin D and prostate cancer risk: A review of the epidemiological literature. Prostate Cancer Prostatic Dis 12:215-226, 2009
16. Yin M, Wei S, Wei Q: Vitamin D receptor genetic polymorphisms and prostate cancer risk: A meta-analysis of 36 published studies. Int J Clin Exp Med 2:159-175, 2009
17. Li H, Stampfer MJ, Hollis JB, et al: A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 4:e103, 2007
18. Ma J, Stampfer MJ, Gann PH, et al: Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 7:385-390, 1998 (Pubitemid 28354126)
19. Ahn J, Albanes D, Berndt SI, et al: Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 30:769-776, 2009
20. Final report on the aspirin component of the ongoing Physicians' Health Study: Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 321:129-135, 1989
21. Christen WG, Gaziano JM, Hennekens CH: Design of Physicians' Health Study II: A randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 10:125-134, 2000 (Pubitemid 30089022)
22. Kure S, Nosho K, Baba Y, et al: Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev 18:2765-2772, 2009
23. Tomlins SA, Rhodes DR, Perner S, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648, 2005 (Pubitemid 41528150)
24. Demichelis F, Fall K, Perner S, et al: TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26: 4596-4599, 2007 (Pubitemid 47037039)
25. Setlur SR, Mertz KD, Hoshida Y, et al: Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100:815-825, 2008 (Pubitemid 351809667)
26. Hollis BW, Kamerud JQ, Kurkowski A, et al: Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer. Clin Chem 42:586-592, 1996
27. Hollis BW, Kamerud JQ, Selvaag SR, et al: Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem 39:529-533, 1993 (Pubitemid 23099026)
28. Skowronski RJ, Peehl DM, Feldman D: Vitamin D and prostate cancer: 1,25 Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960, 1993
29. Krishnan AV, Peehl DM, Feldman D: Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 88:363-371, 2003 (Pubitemid 36119910)
30. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM: Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8:497-511, 2008
31. Attard G, Clark J, Ambroisine L, et al: Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27:253-263, 2008
32. Mehra R, Tomlins SA, Yu J, et al: Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68:3584-3590, 2008
33. Washington MN, Weigel NL: 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology 151:1409-1417, 2010
34. Arai H, Miyamoto K, Taketani Y, et al: A vitamin D receptor gene polymorphism in the translation initiation codon: Effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res 12:915-921, 1997 (Pubitemid 27225001)
35. Miyamoto K, Kesterson RA, Yamamoto H, et al: Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol 11:1165-1179, 1997 (Pubitemid 27278838)
36. Morrison NA, Qi JC, Tokita A, et al: Prediction of bone density from vitamin D receptor alleles. Nature 367:284-287, 1994 (Pubitemid 24051146)
37. Colin EM, Weel AE, Uitterlinden AG, et al: Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3. Clin Endocrinol (Oxf) 52:211-216, 2000 (Pubitemid 30108268)
38. Saijo T, Ito M, Takeda E, et al: A unique mutation in the vitamin D receptor gene in three Japanese patients with vitamin D-dependent rickets type II: Utility of single-strand conformation polymorphism analysis for heterozygous carrier detection. Am J Hum Genet 49:668-673, 1991 (Pubitemid 21891713)
39. Barsony J, Renyi I, McKoy W: Subcellular distribution of normal and mutant vitamin D receptors in living cells: Studies with a novel fluorescent ligand. J Biol Chem 272:5774-5782, 1997 (Pubitemid 27102408)
40. Norman AW, Bishop JE, Bula CM, et al: Molecular tools for study of genomic and rapid signal transduction responses initiated by 1 alpha,25(OH)(2)-vitamin D(3). Steroids 67:457-466, 2002 (Pubitemid 34311760)
41. Baran DT, Sorensen AM, Honeyman TW, et al: 1 Alpha,25-dihydroxyvitamin D3-induced increments in hepatocyte cytosolic calcium and lysophosphatidylinositol: Inhibition by pertussis toxin and 1 beta,25-dihydroxyvitamin D3. J Bone Miner Res 5:517-524, 1990 (Pubitemid 20204511)
42. Beno DW, Brady LM, Bissonnette M, et al: Protein kinase C and mitogen-activated protein kinase are required for 1,25-dihydroxyvitamin D3-stimulated Egr induction. J Biol Chem 270:3642-3647, 1995
43. Caffrey JM, Farach-Carson MC: Vitamin D3 metabolites modulate dihydropyridine-sensitive calcium currents in clonal rat osteosarcoma cells. J Biol Chem 264:20265-20274, 1989 (Pubitemid 20009206)
44. Khare S, Bolt MJ, Wali RK, et al: 1,25 Dihydroxyvitamin D3 stimulates phospholipase C-gamma in rat colonocytes: Role of c-Src in PLC-gamma activation. J Clin Invest 99:1831-1841, 1997
45. Morelli S, de Boland AR, Boland RL: Generation of inositol phosphates, diacylglycerol and calcium fluxes in myoblasts treated with 1,25- dihydroxyvitamin D3. Biochem J 289:675-679, 1993 (Pubitemid 23074948)
46. Wali RK, Baum CL, Sitrin MD, et al: 1,25(OH)2 vitamin D3 stimulates membrane phosphoinositide turnover, activates protein kinase C, and increases cytosolic calcium in rat colonic epithelium. J Clin Invest 85:1296-1303, 1990 (Pubitemid 20123777)
47. Blomberg Jensen M, Andersen CB, Nielsen JE, et al: Expression of the vitamin D receptor, 25-hydroxylases, 1alpha-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer. J Steroid Biochem Mol Biol 121:376-382, 2010
48. Khadzkou K, Buchwald P, Westin G, et al: 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. J Histochem Cytochem 54:355-361, 2006 (Pubitemid 43291280)
49. Liu W, Tretiakova M, Kong J, et al: Expression of vitamin D3 receptor in kidney tumors. Hum Pathol 37:1268-1278, 2006 (Pubitemid 44380280)
50. Menezes RJ, Cheney RT, Husain A, et al: Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev 17:1104-1110, 2008
51. Seubwai W, Wongkham C, Puapairoj A, et al: Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinoma: Implications for therapeutics. Cancer 109:2497-2505, 2007 (Pubitemid 46906469)
52. Silvagno F, Poma CB, Realmuto C, et al: Analysis of vitamin D receptor expression and clinical correlations in patients with ovarian cancer. Gynecol Oncol 119:121-124, 2010